Latest news with #RahulGupta
Time of India
4 days ago
- Time of India
K'taka man held in cyber fraud case amounting to over Rs 1 crore
Cyber fraud Panaji: Goa police on Tuesday arrested a Karnataka resident in alleged connection with a major cyber fraud case involving an amount of over Rs 1 crore. The case was registered at the cybercrime police station based on a complaint lodged by a resident of Old Goa. SP (crime branch) Rahul Gupta said that before May 15, the complainant was induced to invest in a fraudulent trading scheme named 'ASK Smart Prospect Y5', which promised high returns. The accused, using multiple mobile and WhatsApp numbers, manipulated the victim into transferring the said amount to various bank accounts. 'Following an in-depth investigation and financial analysis, a suspect was identified. A police team proceeded to Shivamogga, Karnataka, and arrested 63-year-old resident, K Krishna Murthy,' said Gupta. During interrogation, it was revealed that the accused received Rs 5 lakh from the defrauded amount into his bank account and subsequently transferred the money to his associates. The accused opened a current account under the firm name 'Bappa Machine Pvt Ltd', which is also involved in five cyber complaints in three different states amounting to a total of Rs 6.5 crore, said Gupta. The accused is currently in police custody for three days. Further investigation is ongoing under the supervision of PI Deepak Pednekar, cyber crime police station, Goa.
Associated Press
6 days ago
- Politics
- Associated Press
DEA's Internal Marijuana Resistance: MMJ BioPharma Delays Reflect a Wider Cannabis Rescheduling Crisis
As Former White House Drug Czar Rahul Gupta revealed DEA intentional sabotage, will DEA Administrator Nominee Terrance Cole Address the Marijuana Crisis? Bureaucratic Inaction and Medical Delays Demand Accountability. WASHINGTON, DC / ACCESS Newswire / May 25, 2025 / When former White House Drug Czar Rahul Gupta revealed that the Drug Enforcement Administration (DEA) had intentionally delayed marijuana rescheduling from within its own ranks, it sent shockwaves through the cannabis policy world. For MMJ BioPharma Cultivation, the federally compliant pharmaceutical company developing cannabinoid-based treatments for Huntington's disease and Multiple Sclerosis, this revelation merely confirms what they have endured for years: bureaucratic sabotage from inside the DEA. The similarities between MMJ's stalled license application and the national rescheduling impasse are too glaring to ignore. Both involve DEA officials subverting legal processes, ignoring scientific consensus, and acting contrary to Department of Justice (DOJ) directives. And in both cases, the ultimate cost is borne by suffering patients and U.S. scientific progress. MMJ's Seven-Year Delay: Compliance Met with Contempt MMJ BioPharma Cultivation has followed every federal rule: Yet the DEA has refused to issue a Schedule I Bulk Manufacturing License necessary to grow cannabis for clinical trials. The agency's inaction has persisted for over seven years, despite multiple inspections and full compliance. The delay isn't based on science. It isn't based on law. It's based on unaccountable bureaucrats like DEA Deputy Assistant Administrator Thomas Prevoznik and marijuana policy administrator Matthew Strait, who wield unchecked power behind closed doors. Echoes of the Rescheduling Crisis Gupta's recent statement to The New York Times revealed that the DEA's internal resistance to rescheduling cannabis had torpedoed the Biden administration's efforts. Despite HHS and FDA recommendations, and Attorney General Merrick Garland's approval, DEA leadership stalled the process and raised suspect questions about the medical value of cannabis-a move critics call 'rigged.' Sound familiar? That's precisely what MMJ BioPharma Cultivation has alleged in court: that DEA officials have subverted the Controlled Substances Act and DOJ policies, intentionally obstructing the lawful drug development process. Constitutional Violations, Ignored Directives The Supreme Court's Axon ruling declared the DEA's Administrative Law Judge (ALJ) system unconstitutional. In line with this, DOJ formally informed courts it would no longer defend those ALJ tribunals. Yet MMJ's case was just sent back into that exact invalid hearing structure, scheduled for June 11, 2025. This isn't mere delay. It's institutional defiance of the rule of law. The Real Victims: Patients and Science While DEA officials delay and deflect, patients with progressive neurological disorders continue to suffer. MMJ's therapies could offer relief, but the agency that should be enabling scientific advancement has instead become its greatest obstacle. Meanwhile, as DEA devotes resources to sabotaging federally compliant companies, it admits in its own 2025 National Drug Threat Assessment that cartel-backed operations are thriving in legalized states, exploiting weak oversight. 'The irony is glaring,' said MMJ CEO Duane Boise. 'The DEA blocks lawful drug development while cartels profit. The agency is both gatekeeper and roadblock-and now, a constitutional liability.' Time for Accountability MMJ BioPharma is calling on: 'This is no longer about science or safety,' Boise concluded. 'This is about entrenched power, defiance of the law, and a complete abandonment of the public interest. Congress must act now.' MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-85832 SOURCE: MMJ International Holdings press release
Yahoo
6 days ago
- Business
- Yahoo
DEA's Internal Marijuana Resistance: MMJ BioPharma Delays Reflect a Wider Cannabis Rescheduling Crisis
As Former White House Drug Czar Rahul Gupta revealed DEA intentional sabotage, will DEA Administrator Nominee Terrance Cole Address the Marijuana Crisis? Bureaucratic Inaction and Medical Delays Demand Accountability. WASHINGTON, DC / / May 25, 2025 / When former White House Drug Czar Rahul Gupta revealed that the Drug Enforcement Administration (DEA) had intentionally delayed marijuana rescheduling from within its own ranks, it sent shockwaves through the cannabis policy world. For MMJ BioPharma Cultivation, the federally compliant pharmaceutical company developing cannabinoid-based treatments for Huntington's disease and Multiple Sclerosis, this revelation merely confirms what they have endured for years: bureaucratic sabotage from inside the DEA. The similarities between MMJ's stalled license application and the national rescheduling impasse are too glaring to ignore. Both involve DEA officials subverting legal processes, ignoring scientific consensus, and acting contrary to Department of Justice (DOJ) directives. And in both cases, the ultimate cost is borne by suffering patients and U.S. scientific progress. MMJ's Seven-Year Delay: Compliance Met with Contempt MMJ BioPharma Cultivation has followed every federal rule: Two Investigational New Drug (IND) applications accepted by the FDA. Orphan Drug Designation granted for its proprietary cannabinoid capsule. DEA Schedule I Analytical Laboratory registration issued. Yet the DEA has refused to issue a Schedule I Bulk Manufacturing License necessary to grow cannabis for clinical trials. The agency's inaction has persisted for over seven years, despite multiple inspections and full compliance. The delay isn't based on science. It isn't based on law. It's based on unaccountable bureaucrats like DEA Deputy Assistant Administrator Thomas Prevoznik and marijuana policy administrator Matthew Strait, who wield unchecked power behind closed doors. Echoes of the Rescheduling Crisis Gupta's recent statement to The New York Times revealed that the DEA's internal resistance to rescheduling cannabis had torpedoed the Biden administration's efforts. Despite HHS and FDA recommendations, and Attorney General Merrick Garland's approval, DEA leadership stalled the process and raised suspect questions about the medical value of cannabis-a move critics call "rigged." Sound familiar? That's precisely what MMJ BioPharma Cultivation has alleged in court: that DEA officials have subverted the Controlled Substances Act and DOJ policies, intentionally obstructing the lawful drug development process. Constitutional Violations, Ignored Directives The Supreme Court's Axon ruling declared the DEA's Administrative Law Judge (ALJ) system unconstitutional. In line with this, DOJ formally informed courts it would no longer defend those ALJ tribunals. Yet MMJ's case was just sent back into that exact invalid hearing structure, scheduled for June 11, 2025. This isn't mere delay. It's institutional defiance of the rule of law. The Real Victims: Patients and Science While DEA officials delay and deflect, patients with progressive neurological disorders continue to suffer. MMJ's therapies could offer relief, but the agency that should be enabling scientific advancement has instead become its greatest obstacle. Meanwhile, as DEA devotes resources to sabotaging federally compliant companies, it admits in its own 2025 National Drug Threat Assessment that cartel-backed operations are thriving in legalized states, exploiting weak oversight. "The irony is glaring," said MMJ CEO Duane Boise. "The DEA blocks lawful drug development while cartels profit. The agency is both gatekeeper and roadblock-and now, a constitutional liability." Time for Accountability MMJ BioPharma is calling on: Congress to launch immediate oversight into DEA misconduct. DOJ to enforce its own policies and halt illegal proceedings. DEA Nominee Terrance Cole to commit to ending this sabotage and comply with judicial precedent. "This is no longer about science or safety," Boise concluded. "This is about entrenched power, defiance of the law, and a complete abandonment of the public interest. Congress must act now." MMJ is represented by attorney Megan Sheehan. CONTACT:Madison HiseyMHisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire
Yahoo
6 days ago
- Business
- Yahoo
DEA's Internal Marijuana Resistance: MMJ BioPharma Delays Reflect a Wider Cannabis Rescheduling Crisis
As Former White House Drug Czar Rahul Gupta revealed DEA intentional sabotage, will DEA Administrator Nominee Terrance Cole Address the Marijuana Crisis? Bureaucratic Inaction and Medical Delays Demand Accountability. WASHINGTON, DC / / May 25, 2025 / When former White House Drug Czar Rahul Gupta revealed that the Drug Enforcement Administration (DEA) had intentionally delayed marijuana rescheduling from within its own ranks, it sent shockwaves through the cannabis policy world. For MMJ BioPharma Cultivation, the federally compliant pharmaceutical company developing cannabinoid-based treatments for Huntington's disease and Multiple Sclerosis, this revelation merely confirms what they have endured for years: bureaucratic sabotage from inside the DEA. The similarities between MMJ's stalled license application and the national rescheduling impasse are too glaring to ignore. Both involve DEA officials subverting legal processes, ignoring scientific consensus, and acting contrary to Department of Justice (DOJ) directives. And in both cases, the ultimate cost is borne by suffering patients and U.S. scientific progress. MMJ's Seven-Year Delay: Compliance Met with Contempt MMJ BioPharma Cultivation has followed every federal rule: Two Investigational New Drug (IND) applications accepted by the FDA. Orphan Drug Designation granted for its proprietary cannabinoid capsule. DEA Schedule I Analytical Laboratory registration issued. Yet the DEA has refused to issue a Schedule I Bulk Manufacturing License necessary to grow cannabis for clinical trials. The agency's inaction has persisted for over seven years, despite multiple inspections and full compliance. The delay isn't based on science. It isn't based on law. It's based on unaccountable bureaucrats like DEA Deputy Assistant Administrator Thomas Prevoznik and marijuana policy administrator Matthew Strait, who wield unchecked power behind closed doors. Echoes of the Rescheduling Crisis Gupta's recent statement to The New York Times revealed that the DEA's internal resistance to rescheduling cannabis had torpedoed the Biden administration's efforts. Despite HHS and FDA recommendations, and Attorney General Merrick Garland's approval, DEA leadership stalled the process and raised suspect questions about the medical value of cannabis-a move critics call "rigged." Sound familiar? That's precisely what MMJ BioPharma Cultivation has alleged in court: that DEA officials have subverted the Controlled Substances Act and DOJ policies, intentionally obstructing the lawful drug development process. Constitutional Violations, Ignored Directives The Supreme Court's Axon ruling declared the DEA's Administrative Law Judge (ALJ) system unconstitutional. In line with this, DOJ formally informed courts it would no longer defend those ALJ tribunals. Yet MMJ's case was just sent back into that exact invalid hearing structure, scheduled for June 11, 2025. This isn't mere delay. It's institutional defiance of the rule of law. The Real Victims: Patients and Science While DEA officials delay and deflect, patients with progressive neurological disorders continue to suffer. MMJ's therapies could offer relief, but the agency that should be enabling scientific advancement has instead become its greatest obstacle. Meanwhile, as DEA devotes resources to sabotaging federally compliant companies, it admits in its own 2025 National Drug Threat Assessment that cartel-backed operations are thriving in legalized states, exploiting weak oversight. "The irony is glaring," said MMJ CEO Duane Boise. "The DEA blocks lawful drug development while cartels profit. The agency is both gatekeeper and roadblock-and now, a constitutional liability." Time for Accountability MMJ BioPharma is calling on: Congress to launch immediate oversight into DEA misconduct. DOJ to enforce its own policies and halt illegal proceedings. DEA Nominee Terrance Cole to commit to ending this sabotage and comply with judicial precedent. "This is no longer about science or safety," Boise concluded. "This is about entrenched power, defiance of the law, and a complete abandonment of the public interest. Congress must act now." MMJ is represented by attorney Megan Sheehan. CONTACT:Madison HiseyMHisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire
Time of India
23-05-2025
- Time of India
Bengal man arrested for siphoning off Rs 4 crore from Goa Samagra Shiksha funds
Panaji: A man from West Bengal allegedly siphoned off Rs 4.6 crore from the bank account of Goa Samagra Shiksha Abhiyan (GSSA). These funds were intended for the implementation of school education schemes. The misappropriation occurred without the knowledge of the authorities concerned. Porvorim police arrested one person from West Bengal who is a garment businessman on paper. GSSA holds a savings account in a nationalised bank at the Porvorim branch in the name of 'Goa Sarva Shiksha Abhiyan Society'. The misappropriation came to light in April when an auditor of a private bank pointed out the transactions. Immediately, the bank manager of the private bank approached the GSSA office and highlighted the transactions. When the officials of GSSA approached the nationalised bank, they realised that since 2020 there has been no update of the mobile number despite repeated requests to the bank. It was also found that the new chequebook issued by the nationalised bank to the accused was not registered with the bank. GSSA officials found that the bank cleared the official cheque issued by GSSA and at the same time cleared the cheque issued by the accused without verifying how two different cheques with different signatures were processed. The nationalised bank's manager allegedly even tried to delay providing CCTV footage to GSSA. The bank allegedly updated the new mobile number on forged documents without informing GSSA, and the accused took control of the account. 'Some unknown person fraudulently updated the linked mobile number of the bank account of GSSA and further submitted forged positive-pay system (PPS) slips,' North Goa SP Rahul Gupta said. PPS is a safety mechanism with which the issuer of a high-value cheque attests to its bona fides. Gupta said, 'The accused presented cheques with forged signatures to various banks in various branches all over Goa, which resulted in fraudulent transactions of Rs 4.6 crore approximately.' Based on the transactions and mobile numbers used for committing the crime, one of the account holders was identified in West Bengal, Gupta said. 'He was traced and arrested. All the bank accounts involved have been frozen, and the trail of money is also traced, and subsequent accounts have also been frozen,' Gupta said. 'The arrested accused, a conspirator, provided his bank account, ATM card, and SIM card to a co-accused for a commission of 1% on every transaction and was assured a loan of Rs 50 lakh for his business.' The main accused in the case is yet to be traced. The state project director GSSA, S S Ghadi, said in the complaint that in the bank statement, some suspicious transactions were noticed in the months of Feb, March, and April 2025, which were brought to the notice of the bank for taking necessary action in the matter. 'It is also to bring to your kind notice that this office submitted to the bank a letter requesting the approval of the payment with the single signature of the chief accounts officer during the period from Feb 21, 2025, to March 5, 2025, as the state project director was out of station on official duty,' the complaint said. Ghadi said, 'However, prima facie, it looks like by neglecting our letter, payments were approved with both signatures. Therefore, you are requested to register our complaint and conduct a thorough inquiry with regards to suspicious transactions to recover the amount that has been transferred.'
